Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma.
Budczies J, Mechtersheimer G, Denkert C, Klauschen F, Mughal SS, Chudasama P, Bockmayr M, Jöhrens K, Endris V, Lier A, Lasitschka F, Penzel R, Dietel M, Brors B, Gröschel S, Glimm H, Schirmacher P, Renner M, Fröhling S, Stenzinger A. Budczies J, et al. Among authors: frohling s. Oncoimmunology. 2017 Jan 27;6(3):e1279777. doi: 10.1080/2162402X.2017.1279777. eCollection 2017. Oncoimmunology. 2017. PMID: 28405504 Free PMC article.
Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.
Dietrich S, Hüllein J, Hundemer M, Lehners N, Jethwa A, Capper D, Acker T, Garvalov BK, Andrulis M, Blume C, Schulte C, Mandel T, Meissner J, Fröhling S, von Kalle C, Glimm H, Ho AD, Zenz T. Dietrich S, et al. Among authors: frohling s. J Clin Oncol. 2013 Jul 1;31(19):e300-3. doi: 10.1200/JCO.2012.45.9495. Epub 2013 May 20. J Clin Oncol. 2013. PMID: 23690412 No abstract available.
Recurrent CDKN1B (p27) mutations in hairy cell leukemia.
Dietrich S, Hüllein J, Lee SC, Hutter B, Gonzalez D, Jayne S, Dyer MJ, Oleś M, Else M, Liu X, Słabicki M, Wu B, Troussard X, Dürig J, Andrulis M, Dearden C, von Kalle C, Granzow M, Jauch A, Fröhling S, Huber W, Meggendorfer M, Haferlach T, Ho AD, Richter D, Brors B, Glimm H, Matutes E, Abdel Wahab O, Zenz T. Dietrich S, et al. Among authors: frohling s. Blood. 2015 Aug 20;126(8):1005-8. doi: 10.1182/blood-2015-04-643361. Epub 2015 Jun 11. Blood. 2015. PMID: 26065650 Free article.
Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.
Kordes M, Röring M, Heining C, Braun S, Hutter B, Richter D, Geörg C, Scholl C, Gröschel S, Roth W, Rosenwald A, Geissinger E, von Kalle C, Jäger D, Brors B, Weichert W, Grüllich C, Glimm H, Brummer T, Fröhling S. Kordes M, et al. Among authors: frohling s. Leukemia. 2016 Apr;30(4):937-46. doi: 10.1038/leu.2015.319. Epub 2015 Nov 19. Leukemia. 2016. PMID: 26582644
Anti-programmed cell death-1 therapy in nonmelanoma skin cancer.
Winkler JK, Schneiderbauer R, Bender C, Sedlaczek O, Fröhling S, Penzel R, Enk A, Hassel JC. Winkler JK, et al. Among authors: frohling s. Br J Dermatol. 2017 Feb;176(2):498-502. doi: 10.1111/bjd.14664. Epub 2016 Oct 17. Br J Dermatol. 2017. PMID: 27061826 No abstract available.
Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.
Budczies J, Bockmayr M, Denkert C, Klauschen F, Gröschel S, Darb-Esfahani S, Pfarr N, Leichsenring J, Onozato ML, Lennerz JK, Dietel M, Fröhling S, Schirmacher P, Iafrate AJ, Weichert W, Stenzinger A. Budczies J, et al. Among authors: frohling s. Genes Chromosomes Cancer. 2016 Aug;55(8):626-39. doi: 10.1002/gcc.22365. Epub 2016 May 30. Genes Chromosomes Cancer. 2016. PMID: 27106868
Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.
Chudasama P, Renner M, Straub M, Mughal SS, Hutter B, Kosaloglu Z, Schweßinger R, Scheffler M, Alldinger I, Schimmack S, Persigehl T, Kobe C, Jäger D, von Kalle C, Schirmacher P, Beckhaus MK, Wolf S, Heining C, Gröschel S, Wolf J, Brors B, Weichert W, Glimm H, Scholl C, Mechtersheimer G, Specht K, Fröhling S. Chudasama P, et al. Among authors: frohling s. Clin Cancer Res. 2017 Feb 15;23(4):962-973. doi: 10.1158/1078-0432.CCR-16-0860. Epub 2016 Aug 17. Clin Cancer Res. 2017. PMID: 27535980
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma.
Dieter SM, Heining C, Agaimy A, Huebschmann D, Bonekamp D, Hutter B, Ehrenberg KR, Fröhlich M, Schlesner M, Scholl C, Schlemmer HP, Wolf S, Mavratzas A, Jung CS, Gröschel S, von Kalle C, Eils R, Brors B, Penzel R, Kriegsmann M, Reuss DE, Schirmacher P, Stenzinger A, Federspil PA, Weichert W, Glimm H, Fröhling S. Dieter SM, et al. Among authors: frohling s. Ann Oncol. 2017 Jan 1;28(1):142-148. doi: 10.1093/annonc/mdw446. Ann Oncol. 2017. PMID: 27687311 Free article.
310 results